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302 F. Arslan et al.contractile performance during 28 days follow-up. Within an hour after reperfusion, exosome treatment increased levels of
ATP and NADH, decreased oxidative stress, increased phosphorylated-Akt and phosphorylated-GSK-3β, and reduced
phosphorylated-c-JNK in ischemic/reperfused hearts. Subsequently, both local and systemic inflammation were significantly
reduced 24 h after reperfusion. In conclusion, our study shows that intact exosomes restore bioenergetics, reduce oxidative
stress and activate pro-survival signaling, thereby enhancing cardiac function and geometry after myocardial I/R injury. Hence,
mesenchymal stem cell-derived exosomes are a potential adjuvant to reperfusion therapy for myocardial infarction.
© 2013 Elsevier B.V. All rights reserved.Introduction
Myocardial infarction (MI) and related complications
(e.g. heart failure) are a great socio-economic burden to
society and healthcare systems. Recent advances in (inter-
ventional) cardiology have resulted in timely and optimized
coronary flow restoration through the culprit artery. Subse-
quently, more patients survive the initial infarction, but are
susceptible to heart failure or other infarct-related com-
plications (International Cardiovascular Disease Statistics,
2004). The major determinant for heart failure and other
complications related to MI is infarct size (Schwartz et al.,
2011). The increase in morbidity after MI triggered the search
for adjunctive therapeutics to further limit excessive tissue
loss and enhance cardiac performance. Pre-clinical studies
show a great potential for engineered heart tissue for replace-
ment therapy (Naito et al., 2006; Zimmermann et al., 2006)
while stem cell injections may be promising in the treatment
of patients with acute MI (Martin-Rendon et al., 2008).
Interestingly, there is increasing evidence showing that the
observed therapeutic effects are partly mediated by stem cell
secretion. This so called ‘paracrine hypothesis’ has gained
much attention and is supported by recent experimental data
(Gnecchi et al., 2008). It has been shown that mesenchymal
stem cell-conditioned medium (MSC-CM) enhances cardio-
myocyte and/or progenitor survival after hypoxia-induced
injury (Chimenti et al., 2010; Deuse et al., 2009; Gnecchi et
al., 2006; Matsuura et al., 2009; Rogers et al., 2011).
Furthermore, MSC-CM induces angiogenesis in the infarcted
myocardium (Chimenti et al., 2010; Deuse et al., 2009; Li et
al., 2010). We have shown in both murine and porcine models
of myocardial ischemia/reperfusion (I/R) injury that MSC-CM
reduces infarct size (Timmers et al., 2007). High performance
liquid chromatography (HPLC) and dynamic light scatter (DLS)
analyses revealed that MSCs secrete cardioprotective micro-
particles with a hydrodynamic radius ranging from 50 to 65 ηm
(Chen et al., 2011; Lai et al., 2010b)). Furthermore, the
therapeutic efficacy of MSC-derived exosomes was indepen-
dent of the tissue source for the MSCs. For example, exosomes
from human embryonic stem cell-derived MSCs were similar to
those derived from other fetal tissue sources (e.g. limb,
kidney). This suggests that secretion of therapeutic exosomes
may be a general property of all MSCs (Lai et al., 2010a).
Exosomes are bi-lipid membrane vesicles with a diameter
of 50–100 ηm. They are secreted by various cell types
through the fusion of multivesicular bodies with the plasma
membrane. Exosomes carry a complex cargo load of proteins
and RNA with the potential to effect many cellular pro-
cesses and pathways. They are involved in complex cellular
interactions such as immune responses, intercellular com-
munication and antigen presentation (Thery et al., 2009).
Multivesicular bodies store the exosomes within the cell andrelease them upon fusion with the plasma membrane. The
identification of exosomes as the cardioprotective factor
in MSC secretion makes it a potential therapeutic tool in
myocardial infarction. In contrast to cell-based therapy,
MSC-derived exosomes provide an ‘off-the-shelf’ therapeu-
tic. Furthermore, exosomes are potentially safer as they are
non-viable and will incur less manufacturing and storage
costs. Although we previously described that exosomes
reduce infarct size in mice (Lai et al., 2010a) the functional
consequence and the molecular alterations in vivo respon-
sible for its cardioprotective actions remain unknown.
We have recently profiled the proteome of ischemic/
reperfused mouse hearts (Li et al., 2012) and MSC-derived
exosomes (Lai et al., 2013), to elucidate a molecular
mechanism for the cardioprotective action of MSC-derived
exosomes. Briefly, we found that the most significant
proteomic changes in ischemic/reperfused mouse hearts
were the depletion of proteins in fatty acid (FA) oxidation,
glycolysis, tricarboxylic acid (TCA) cycle, redox homeostasis,
gluthatione S-transferase and heat shock proteins. We also
observed accumulation of proteins involved in apoptosis and
the electron transport chain (ETC) (Li et al., 2012). Taken
together, the observed proteomic changes predicted re-
duced ATP production, increased oxidative stress and
apoptosis; all are key features of cell death after myocardial
I/R injury (Ovize et al., 2010; Yellon and Hausenloy, 2007).
Interestingly, the predicted biochemical changes as a result
of the depletion or accumulation could be reversed or
circumvented by the N800 proteins found in our MSC-derived
exosomes (data available at www.exocarta.org; Lai et al.,
2013. MSC exosomes were found to contain all five enzymes
in the ATP generating stage of glycolysis namely glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), phosphoglycer-
ate kinase (PGK), phosphoglucomutase (PGM), enolase (ENO)
and pyruvate kinase m2 isoform(PKm2) as well as the
phosphorylated PFKFB3 which upregulates phosphofructose
kinase, the rate limiting glycolytic enzyme. This glycolytic
potential was evident when exposure to MSC exosomes
increased ATP production in oligomycin-treated H9C2
cardiomyocytes in which oxidative phosphorylation was
inhibited. Furthermore, oxidative stress was reduced via
peroxiredoxins and glutathione S-transferases in MSC-
derived exosomes. Finally, we found that MSC-derived
exosomes have enzymatically active CD73. CD73 is the
major enzyme responsible for the formation of extracellular
adenosine from released adenine nucleotides (Zimmermann,
2000). We have shown that exosomes activate adenosine
receptors and induce adenosine-induced phosphorylation of
ERK1/2 and Akt in H9C2 cardiomyocytes (Li et al., 2012).
In the present study, we examined the above-mentioned
properties of MSC-derived exosomes to limit cell death after
myocardial I/R injury in vivo. We show that intact exosomes
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we demonstrate that, in line with our in vitro data, exosomes
exert a therapeutic effect via increased ATP production,
decreased oxidative stress and induced PI3K/Akt signaling.Materials and methods
Animals and experimental design
Male C57Bl6/J mice (10–12 weeks old, 25–30 g) received
standard diet and water ad libitum. Saline or exosomes were
administered intravenously via the tail vein, 5 min before
reperfusion. Myocardial infarction was induced by temporary
left coronary artery ligation, just below the left atrial
appendage as described previously (Arslan et al., 2010b).
Where possible, recommendations from the National Heart
Lung and Blood Institute (NHLBI) Working Group on the
Translation of Therapies for Protecting the Heart from
Ischemia (Bolli et al., 2004) were applied; the surgeon was
blinded for the treatment. Digital images of the infarcts were
encrypted before being analyzed by the researcher. Heart
function and geometry assessments were done by a technician
blinded to treatment. All animal experiments were performed
in accordance with the Directive 2010/63/EU of the European
Parliament, national guidelines on animal care and with prior
approval by the Animal Experimentation Committee of Utrecht
University.Myocardial I/R injury in vivo
Mice were anesthetized with a mixture of fentanyl (Jansen-
Cilag) 0.05 mg/kg, midazolam (Dormicum, Roche) 5 mg/kg
and medetomidine 0.5 mg/kg through an intraperitoneal
injection. The adequacy of anesthesia was monitored by
checking interdigital pain reflexes, righting reflexes, limb/
muscle tone and spontaneous breathing frequency. Core body
temperature was maintained around 37 °C during surgery by
continuous monitoring with a rectal thermometer and auto-
matic heating blanket. Mice were intubated and ventilated
(Harvard Apparatus Inc.) with 100% oxygen. The left coronary
artery (LCA) was ligated for 30 min using an 8-0 Ethilon
(Ethicon) with a section of polyethylene-10 tubing placed over
the LCA. Ischemia was confirmed by bleaching of the
myocardium and transient tachycardia. In sham operated
animals the suture was placed beneath the LCA without
ligating. Reperfusion was initiated by releasing the ligature
and removing the polyethylene-10 tubing. Reperfusion of the
endangered myocardium was characterized by typical hyper-
emia in the first fewminutes. In a subgroup of mice, a piece of
the loosened suture was left in place to determine the
area-at-risk (AAR) during termination. The chest wall was
closed and the animals received subcutaneously atipamezole
(Antisedan, Pfizer) 2.5 mg/kg, flumazenil (Anexate, Roche)
0.5 mg/kg and buprenorphine (Temgesic, Schering-Plough)
0.1 mg/kg.
Prior to termination, mice were anesthetized as de-
scribed above before cervical dislocation. Hereafter, the
hearts were rinsed with saline and subsequently explanted
for further biochemical and/or histological analysis.Exosome purification
Exosomes were purified from huES9.E1 derived MSC con-
ditioned media (CM) using HPLC, as described earlier (Lai
et al., 2010a; Sze et al., 2007). Briefly, to prepare the CM,
80% confluent HuES9.E1 cell cultures were washed three
times with PBS and cultured overnight in a chemically
defined medium consisting of DMEM without phenol red
(Invitrogen) and supplemented with insulin, transferrin, and
selenoprotein (ITS; Invitrogen), 5 ng/ml FGF2 (Invitrogen),
5 ng/ml PDGF AB (Peprotech, Rocky Hill, NJ), glutamine–
penicillin–streptomycin, and β-mercaptoethanol. The cul-
tures were then rinsed three times with PBS, and fresh
defined medium was added. After 3 days, the medium was
collected and centrifuged at 500 g, and the supernatant was
filtered using a 0.2-μm filter. No serum was used in the
preparation of the CM and the cells were not stimulated.
Serum-free CM collected from MSCs culture was concen-
trated 50× by tangential flow filtration using a membrane
with a 100 kDa MWCO (Sartorius, Goettingen, Germany).
Hereafter, CM was passed through chromatography columns
(TSK Guard column SWXL, 6×40 mm and TSK gel G4000
SWXL, 7.8×300 mm, Tosoh Corp., Tokyo, Japan). Exosomes
were collected from the first peak of the elution, concen-
trated using 100 kDa MWCO filter (Sartorius). Exosomes were
filtered with a 0.22 μm filter before storage at −80 °C.
Infarct size
Infarct size (IS) as a percentage of the area-at-risk (AAR) was
determined using Evans' blue dye injection and TTC staining,
1 day after reperfusion (n=6/group).
Mice were anesthetized as described above with a
mixture of fentanyl, midazolam and medetomidine. The
LCA was ligated once again at the level marked by the suture
left in place. Evans' blue dye (4%) was injected via the
thoracic aorta in a retrograde fashion. By doing so, one can
demarcate non-ischemic region in order to determine the
AAR; the extent of myocardial tissue that underwent
ischemia (i.e. endangered myocardium). Hearts were rapidly
explanted, rinsed in 0.9% saline and put in −20 °C freezer
for 1 h. Hereafter, hearts were mechanically sliced into four
1-mm cross sections. Heart sections were incubated in 1%
triphenyltetrazolium-chloride (Sigma-Aldrich) at 37 °C for
15 min before placing them in formaldehyde for another
15 min. Viable tissue stains red and infarcted tissue appears
white. Heart sections were digitally photographed (Canon
EOS 400D) under a microscope (Carl Zeiss®). IS, AAR and
total LV area were measured using ImageJ software (version
1.34). Infarct size was corrected for the weight of the
corresponding heart slice.
Myocardial I/R injury ex vivo
Mice (n=4/group) were given heparin 50 IE subcutaneously
and were operated under general anesthesia as de-
scribed above with a mixture of fentanyl, midazolam and
medetomidine. The suture was placed beneath the LCA in
vivo without ligating. Hereafter, the heart was excised and
aortic root was canulated and perfused in the Langendorff
setup. After 10 min recovery, the suture was tightened to
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the perfusion buffer was changed for a second buffer
containing 0.4 μg/ml MSC-derived exosomes or control.
Reperfusion was initiated by releasing the suture. Following
3 h of reperfusion, Evans' blue dye was injected after
re-ligating the suture to demarcate the AAR. Subsequently,
TTC staining was performed for infarct size assessment.
Cardiac magnetic resonance imaging
Twenty-six mice (n=10/group in ischemic and n=6/group in
sham operated mice) underwent serial assessment of cardiac
dimensions and function by high resolution magnetic reso-
nance imaging (MRI, 9.4 T, Bruker, Rheinstetten, Germany)
under isoflurane anesthesia before, 1, 7 and 28 days after MI.
Long axis and short axis images with 1.0 mm interval
between the slices were obtained and used to compute
end-diastolic volume (EDV, largest volume) and end-systolic
volume (ESV, smallest volume). The ejection fraction (EF)
was calculated as 100∗ (EDV−ESV)/EDV. Wall thickness (WT)
and systolic wall thickening (SWT) were assessed from both
the septum (remote myocardium) and free wall (infarct
area). All MRI data are analyzed using Qmass digital imaging
software (Medis, Leiden, the Netherlands).
Pressure–volume loop recordings
In a subset of mice, invasive assessment of cardiac per-
formance and LV pressure development was performed
28 days after infarction. Mice were anesthetized as de-
scribed above with a mixture of fentanyl, midazolam and
medetomidine. A Millar 1.4 F pressure catheter (model
SPR-839) was inserted in a retrograde fashion via the right
common carotid artery. Systolic function was assessed by LV
end-systolic pressure and dP/dtmax, whereas diastolic
function by LV end-diastolic pressure and dP/dtmin.
Immunohistochemistry
Upon termination (as described above), hearts were rinsed with
saline and excised and fixated in 4% formaldehyde and embedded
in paraffin. Paraffin sections were stained for Ly-6G (for
neutrophils; rat anti-mouse Ly-6G 1:100, Abcam, Cambridge,
United Kingdom) and MAC-3 (for macrophages; rat anti-mouse
MAC-3 1:30, BD Pharmingen, Breda, the Netherlands).
Sections were stained by overnight incubation with the first
antibody at 4 °C for MAC-3 or by 1 h incubation at RT for Ly-6G.
Before staining, sections were deparaffinized and endogenous
peroxidase was blocked by 30 min incubation in methanol
containing 1.5% H2O2. Antigen retrieval was performed by
20 min boiling in citrate buffer (MAC-3 and Ly-6G).
For MAC-3, sections were pre-incubated with normal goat
serum and incubated with the primary antibody (1:30 over-
night at 4 °C). Sections were then incubated for 1 h at RT
with a biotin labeled secondary antibody, followed by 1 h
incubation with streptavidin–horseradish peroxidase at RT
and developed with AEC.
For Ly-6G, sections were incubated with the primary
antibody (1:100 for 1 h at RT). Sections were then incubated
for 30 min with a secondary antibody followed by 30 min
incubation with Powervision poly-HRP anti-rabbit IgG(ImmunoVision Technologies, Daily City, USA). The staining
was immediately visualized with Vector NovaRED™ substrate
kit following the manufacturer's instructions (Vector Labo-
ratories Inc., Burlingame, USA).
Macrophage and neutrophil counts were assessed per heart
section within the infarcted area using Olympus Cell^P
software. The AEC (for MAC-3) and NovaRED™ (for Ly-6G)
staining on cells were digitalized (i.e. RGB-HSI color codes) for
each heart section. Neutrophils and macrophages were defined
as “particles” with i) staining-positivity and ii) had an adjacent
minimum pixel count of 5 for neutrophils and 20 for
macrophages. Initial manual identification of neutrophils and
macrophages revealed that a minimum pixel count of 5 and 20
correlateswith the actual cell size. Each particle containing 5 or
20 adjacent pixels positive for, respectively, Ly-6G or MAC-3
staining was counted as 1 cell by the software.
Peripheral white blood cell (WBC) count was determined
using a Cell-Dyn® 1800 (Abbott Laboratories) differential
analyzer.
Protein isolation
Total protein was isolated from snap frozen infarcted heart
sections using 40 mM Tris pH 7.4.
Flow cytometry
Phosphorylated target protein for Akt (Ser473), glucogen
synthase kinase-3α/β (GSK-3α/β; Ser21/Ser9), extracellular
signal-regulated kinases-1/2 (ERK1/2; Thr202/Tyr204),
c-Jun N-terminal kinase (c-JNK; Thr183/Tyr185) were mea-
sured using the Bio-Plex Multiplex Assay (Bio-Rad Laborato-
ries) according to the instructions of the manufacturer, after
1:5 dilution in assay buffer.
ATP/ADP and NADH/NAD+
ATP/ADP and NADH/NAD+ ratios were measured in the
ischemic area of mice. MI was induced as described earlier.
After 0 min, 5 min and 30 min of reperfusion, the ischemic
area was excised and snap frozen using liquid nitrogen.
Frozen tissue samples were homogenized with 1 ml extrac-
tion buffer and supernatant was collected after spinning at
14,000 g for 5 min. Hereafter, the supernatant was passed
through 10 kDa MWCO filter (Biovision) before performing
the ATP/ADP and NADH/NAD+ assays according to the
manufacturer's protocol (Biovision, Mountain view, CA).
Oxidative stress assay
Oxidative stress was measured on 10 μg Tris-isolated protein
using the Oxyblot protein oxidation detection kit (S7150;
Millipore, Billerica MA, USA). Measurements were performed
according to the manufacturer's instructions.
Statistical analysis
Data are represented as mean±SEM. One-way ANOVA with
post-hoc 2-sided Dunnett t-test adjustment (saline was set as
control) was used for infarct size comparison between the
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sons. All statistical analyses were performed using SPSS 15.1.1.
and pb0.05 was considered significant. The authors had full
access to and take full responsibility for the integrity of the data.
All authors have read and agreed to the manuscript as written.Results
Intact exosomes reduce myocardial I/R injury
through direct interaction with myocardial cellsThirty minutes ischemia followed by 24 h reperfusion in
saline treated animals resulted in 39±1.8% infarction within
the AAR (IS/AAR; Fig. 1A). A single intravenous bolus of
exosomes 5 min prior to reperfusion reduced infarct size by
45% (21±2.2% IS/AAR; pb0.001), in a dose dependentFigure 1 MSC-derived exosomes reduce myocardial I/R injury in
area-at-risk (AAR) 1 day after I/R injury; *pb0.001, †p=0.001 and ‡
ventricle (LV). Each bar represents mean±SEM, n=6/group for in vimanner. Infarct size reduction in myocardial I/R injury is
achieved by either enhanced cardiomyocyte viability, re-
duced detrimental activation of blood components or both
Arslan et al., 2008, 2010b; Yellon and Hausenloy, 2007). We
performed ex vivo I/R experiments in the Langendorff setup,
to determine the relative contribution of parenchymal and
circulating cells to the cardioprotection mediated by exo-
somes. Three hours reperfusion with normal buffer after
30 min ischemia resulted in 49±5.3% IS/AAR. Exosome-
containing buffer perfusion just prior to reperfusion signif-
icantly reduced infarct size to the same extent as in the in
vivo situation (23±1.5% IS/AAR; p=0.002). This suggests that
exosomes interact directly with cardiac cells to reduce
infarct size. It is postulated that exosomes are internalized
by target cells by endocytosis or phagocytosis in order to
release their content (Feng et al., 2010; Tian et al., 2010).
For this reason, we tested if the cardioprotection was
dependent on the integrity of the exosomes as lipidvivo and ex vivo. A, Infarct size (IS) as a percentage of the
p=0.001 compared to saline. B, AAR as a percentage of the left
vo and n=4/group for ex vivo experiments.
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physically disrupted by vigorous agitation in a homogenizer
before administration. The homogenized exosomes failed to
reduce infarct size in vivo (37±3.0% IS/AAR; p=.994). In all
experiments, the extent of myocardium at risk was similar in
all groups (mean AAR/LV=40±1.1%; Fig. 1B).Exosome treatment prevents left ventricular
dilatation and improves cardiac performance
We next examined the functional consequences of exosome
treatment during 28 days follow-up. We performed serial
cardiac MRI measurements to assess both left ventricular
(LV) function and geometry after I/R injury. There were no
differences in LV function and dimensions at baseline. TheFigure 2 MSC-derived exosomes prevent LV dilation and improve
volume (EDV, μl); *p=0.029 and †p=0.006 compared to saline. B,
compared to saline. C, Ejection fraction (EF, %); *p=0.035, †p=0.0
infarct area (WT, mm); *pb0.001 compared to baseline and †p=0.04
wall thickening (SWT, %); *p=0.011, †p=0.042 and ‡p=0.040 com
compared to saline. Representative MRI images are shown. Note the
animals. Each bar represents mean±SEM, n=10/group for ischemic/infarct size reduction in exosome treated animals translated
into significant preservation of both end-diastolic and
-systolic volume (EDV, ESV) during follow-up. In addition,
ejection fraction was significantly improved after exosome
treatment at all time points (Figs. 2A–C). Wall thickness
(WT) of the infarcted area (free wall) was equally increased
in saline and exosome treated animals 1 day after reperfu-
sion (Fig. 2D), presumably caused by tissue edema. Although
infarct size was reduced, exosome treatment did not reduce
reperfusion-induced edema as shown by equal increase in
thickness of the free wall (infarct area) 1 day after
reperfusion. The similar extent of tissue edema at day 1 in
the MRI studies indicated that the amount of endangered
myocardium did not differ between the groups. However,
exosome treatment resulted in decreased thinning of the
infarct area during scar maturation. This finding was in linesystolic function after myocardial I/R injury. A, End-diastolic
End-systolic volume (ESV); *p=0.04, †p=0.017 and ‡p=0.002
15 and ‡p=0.002 compared to saline. D, Wall thickness of the
compared to saline. E, WT of the remote myocardium. F, systolic
pared to saline. G, SWT of the remote myocardium; *p=0.012
increased LV dimensions at systole and diastole in saline treated
reperfused animals n=6/group for sham operated mice.
Figure 2 (contnued).
Table 1 Invasive left ventricular pressure measurements
28 days after infarction.
Saline Exosomes p
BPM 480±7 476±3 .60
ESP 110±2 137±10 .12
EDP 15±1 7±1 .009
dP/dTmax 7496±152 8951±246 .009
dP/dTmin −6680±75 −8241±396 .009
Data are represented as mean±SEM, n=5/group. BPM = beats per
minute, ESP = end-systolic pressure, EDP = end-diastolic pressure.
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ment. There were no differences in wall thickness of the
remote myocardium between the groups (Fig. 2E). The
higher extent of viable tissue after exosome treatment also
significantly improved systolic thickening of the infarcted
area at all time points (Fig. 2F), and in the remote
myocardium 28 days after infarction (Fig. 2G).
At day 28, we also assessed the hemodynamic conse-
quences using invasive LV pressure–volume loop recordings
after exosome treatment. Consistent with improved LV
function and geometry, we observed higher contractilityand relaxation and reduced end-diastolic pressure (EDP) in
exosome treated animals (Table 1).
Exosome treatment restores energy depletion and
redox state within 30 min after I/R
Mitochondrial dysfunction is one of the most important
determinants of viability loss after I/R injury (Murphy and
Steenbergen, 2008). Mitochondrial dysfunction aggravates
the loss of ATP and NADH during ischemia where Kreb's cycle
and oxidative phosphorylation are inhibited by the lack of
oxygen. During reperfusion, ATP production is again dis-
rupted by depletion of enzymes essential for ATP produc-
tion. Restoring ATP and NADH levels will therefore be critical
for the recovery of the ischemic/reperfused myocardium.
We observed that within 30 min after reperfusion, the ATP/
ADP and NADH/NAD+ ratios in exosome-treated animals
were significantly increased (Figs. 3A and B). In addition, the
extent of oxidative stress, as a hallmark feature of myo-
cardial I/R injury, was also reduced within the first hour of
reperfusion (Fig. 3C). These data demonstrate that exosome
treatment is highly effective in eliciting a rapid biochemical
response to restore ATP and NADH levels and to reduce
oxidative stress.
Exosome treatment phosphorylates Akt/GSK3
pathway and inhibits c-JNK signaling after I/R
Paracrine action of MSC secretion has been shown to be
mediated via enhanced phosphorylation of survival path-
ways, especially of PI3K/Akt pathway (Chimenti et al., 2010;
Deuse et al., 2009; Gnecchi et al., 2006; Gnecchi et al.,
2008; Matsuura et al., 2009). Recently, we have shown that
exosomes can activate adenosine receptors and subsequently
phosphorylate PI3K/Akt pathway in vitro using H9C2
cardiomyocytes (Li et al., 2012). In the present study,
exosome treatment elicited an immediate and significant
increase in Akt and GSK3 phosphorylation within an hour after
reperfusion, and this increase was maintained over the next
24 h (Figs. 4A and B). ERK1/2 phosphorylation has also shown
to be protective in myocardial I/R injury (Murphy and
Steenbergen, 2008), however, was not altered by exosome
treatment (Fig. 4C). Phosphorylation of c-JNK, a known
activator of pro-apoptotic signaling, was rapidly and signifi-
cantly reduced in exosome treated animals within 1 h
reperfusion (Fig. 4D). Total protein levels did not differ
between saline and exosome treated animals (Fig. S1).
Figure 3 MSC-derived exosomes restore ATP/ADP, NADH/NAD+
levels and reduce oxidative stress. Tissue levels of A, ATP/ADP;
*p=0.047 compared to saline. B, NADH/NAD+; *p=0.027 com-
pared to saline. C,Mean oxidized protein levels at 1 h reperfusion;
*p=0.043 compared to saline. Each bar represents mean±SEM,
n=6/group/time point.
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Myocardial I/R is characterized by accentuated cardiac and
systemic inflammation (Arslan et al., 2008, 2010a, 2011).Cardiac inflammation was assessed by neutrophil and macro-
phage infiltration. Exosome treatment reduced neutrophil
and macrophage infiltration in the hearts at days 1 and 3
after reperfusion (Figs. 5A and B). High peripheral white
blood cell (WBC) count is associated with larger infarct size,
worse cardiac performance and poor clinical outcome
(Barron et al., 2001; Bauters et al., 2007; Chia et al., 2009;
Prasad et al., 2007; Smit et al., 2008). In line with reduced
infarct size and improved cardiac performance, exosome
treated animals exhibited significantly reduced WBC count
compared to saline treated mice after I/R injury (Fig. 5C).Discussion
Previous studies have shown that MSC transplantation
improves cardiac function after infarction. The initial
hypothesis that this efficacy was mediated by the engraft-
ment and differentiation of transplanted MSCs to replace
injured tissues is increasingly untenable. Most studies
suggest that MSCs mediate their therapeutic efficacy
through the secretion of paracrine factors (Chimenti et al.,
2010; Gnecchi et al., 2005, 2006, 2008). Like others (Deuse
et al., 2009; Matsuura et al., 2009; Rogers et al., 2011), we
have demonstrated that culture medium conditioned by
MSCs reduces I/R injury in a pig and mouse model (Timmers
et al., 2007). We identified the active component in this CM
as an exosome, a 50–100 ηm bi-lipid membrane secreted
microvesicle (Lai et al., 2010a, 2010b).
In this study, we demonstrated that exosomes not
only reduced infarct size, but also resulted in a long-term
preservation of cardiac function and reduced adverse
remodeling. Interestingly, the therapeutic effect of MSC-
derived exosomes was dependent on their physical integrity
such that vigorous agitation and homogenization, likely to
disrupt the bi-lipid membrane, prevented cardioprotection.
These observations are consistent with the reported uptake
of exosomes by cells via endocytosis or phagocytosis (Feng et
al., 2010; Tian et al., 2010). More specifically, we have also
demonstrated that MSC-derived exosomes are taken up by
H9C2 cardiomyocytes (Chen et al., 2010). Furthermore, ex
vivo Langendorff experiments revealed that exosomes are
able to reduce infarct size to the same extent as in the in
vivo situation. These findings strongly indicate that exo-
somes exert their therapeutic effect via viability enhance-
ment of cardiac tissue and do not require the presence of
circulating blood cells. Unfortunately, we were not able to
follow exosomes in vivo after administration. Both fluores-
cent (GFPpos-MSC secreted GFPpos-exosomes and ex vivo
protein labeling) and radioactive (111In-oxinate) labeling
proved to be too insensitive for detection (data not shown).
The main issue is that the efficacious dosage is relatively low
at 0.1–0.4 μg per mouse. More sensitive labeling techniques
are needed to explore the dynamics of exosomes after in
vivo administration.
Our recent proteomic profiling of the ischemic/
reperfused heart (Li et al., 2012) and MSC-derived exosome
(Li et al., 2012; www.exocarta.org) demonstrated that many
of the hallmark biochemical features of reperfusion injury,
namely ATP deficit, oxidative stress and cell death are
underpinned by either depletion or accumulation of proteins
in the reperfused ischemic heart tissues. MSC-derived
Figure 4 MSC-derived exosomes induce phosphorylation of Akt and GSK3, and reduce c-JNK phosphorylation after myocardial I/R
injury. Tissue levels of A, phospho-Akt (MFI); *p=0.025 and †p=0.025 compared to saline. B, phospho-GSK3α/ß; *p=0.025 and
†p=0.016 compared to saline. C, phospho-ERK1/2. D, phospho-c-JNK; *p=0.045 compared to saline. Each bar represents mean±SEM,
n=6/group/time point.
309MSC-derived exosomes enhance cardiac function and geometry after myocardial I/R injuryexosomes have either complementary or compensating
proteins to revert or circumvent these biochemical features.
Based on the proteomic composition of the ischemic heart
and exosomes, we hypothesized that MSC-derived exosomes
elicited protection against myocardial I/R injury. The
mode of action may be by replenishing depleted glycolytic
enzymes to increase ATP production and supplementing
the reperfused cardiomyocytes with additional protein
components of the cellular antioxidant system (such as the
peroxiredoxins and glutathione S-transferases) to reduce
oxidative stress and activating adenosine-mediated RISK
pathway to reduce cell death (Li et al., 2012).
Consistent with our hypothesis, we observed that within
an hour of reperfusion, exosome treatment significantly
increased tissue level of ATP and NADH in the heart. We
presumed that this increase resulted from increased glycolysis
through replenishment by glycolytic enzymes from exosomes. It
should be noted that in ischemic/reperfused myocardium, only
glycolytic but not the ETC proteins were depleted (Li et al.,
2012). In fact, the level of several ETC proteins was increased.
Therefore increasing glycolytic flux in the reperfused ischemic
myocardium would increase ATP production not only byglycolysis but also by oxidative phosphorylation. Similarly, we
hypothesized that anti-oxidants such as peroxiredoxins and
glutathione S-transferases in exosomes could supplement
depleted cellular antioxidants in ischemic/reperfused myocar-
dium. In line with our hypothesis, oxidative stress was reduced
in exosome-treated mice. Finally, we also predicted that the
presence of enzymatically active CD73 on exosomes would
produce adenosine from extracellular ATP to activate RISK and
enhance myocardial viability (Hausenloy and Yellon, 2004). The
importance of RISK such as PI3 kinase–Akt in limiting reperfu-
sion injury was recently highlighted in a position paper from the
European Society of Cardiology (Ovize et al., 2010). Adenosine
has been shown to be efficacious in limiting infarct size in
animal models and human trials (Headrick and Lasley, 2009).
More importantly, CD73 has been shown to be the major
enzyme responsible for the formation of extracellular aden-
osine from released adenine nucleotides (Zimmermann,
2000). Consistent with the observed infarct size reduction,
exosome treatment significantly increased Akt and GSK3
phosphorylation. Incidentally, pro-apoptotic phosphorylation
of c-JNK was reduced. The cause of this reduction remains to
be determined.
Figure 5 MSC-derived exosomes reduce inflammation after myocardial I/R injury. A, Neutrophil influx (Ly6-Gpos cells per heart
section); *p=0.016 compared to saline. B, Macrophage influx (MAC3pos cells per heart section). Representative staining are shown.
C, Peripheral white blood cell counts after myocardial I/R injury; *p=0.045 and †p=0.009 compared to saline. Each bar represents
mean±SEM, n=6/group/time point.
310 F. Arslan et al.Finally, we observed decreased leukocyte influx in exo-
some treated animals. It is likely that the reduced influx is
secondary to the reduced cardiac injury after exosome
treatment, since leukocyte influx did not differ between the
groups at 1 h reperfusion. In addition, we found that the
reduced infarct size and improved cardiac performance
were associated with low WBC counts in exosome treated
animals. This finding is in line with clinical studies in which
infarct size and clinical outcome is directly proportional to
WBC count (Barron et al., 2001; Bauters et al., 2007; Chia
et al., 2009; Prasad et al., 2007).
The identification of exosomes as the cardioprotective
factor in MSC secretion provides an attractive safer and less
costly ‘off-the-shelf’ therapeutic alternative to cell therapy
in the treatment of myocardial infarction. Exosomes will
become more attractive if we are able to replicate their
efficacy in an ongoing study involving intracoronaryinjection of exosomes during the reperfusion phase in a
porcine model of myocardial I/R injury (Arslan et al., 2012).Conclusions
We have shown that MSC-derived exosomes rapidly activate
multiple cardioprotective pathways to reduce infarct size
and prevent heart function deterioration after myocardial
I/R injury. Our study demonstrates that a single intravenous
administration of MSC-derived exosomes is effective when
administered in the late ischemic period, just prior to
reperfusion. For these reasons, MSC-derived exosomes are a
potential candidate for adjunctive therapy for patients
suffering from acute myocardial infarction.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.01.002.
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